Working... Menu
Trial record 8 of 57 for:    Recruiting, Not yet recruiting, Available Studies | Arthroscopy

Chloroprocaine Outpatient

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03365752
Recruitment Status : Recruiting
First Posted : December 7, 2017
Last Update Posted : December 19, 2018
Information provided by (Responsible Party):
Hospital for Special Surgery, New York

Brief Summary:
Outpatient knee surgeries with duration of less than one hour pose a challenge to the use of spinal anesthesia given that traditional agents remain in effect for 2-3 hours, thus creating a mismatch between length of surgery and anesthetic resolution. The investigators hypothesize that the use of chloroprocaine can combine the benefits of a short spinal anesthetic while avoiding the side effects of a general anesthetic, thus promoting earlier discharge.

Condition or disease Intervention/treatment Phase
Knee Arthroscopy Drug: Chloroprocaine Drug: Mepivacaine Drug: General Anesthetics Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison Study to Facilitate Earlier Discharge: Spinal Versus General Anesthesia for Outpatient Knee Surgeries, a Randomized Controlled Study
Actual Study Start Date : June 24, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Chloroprocaine Drug: Chloroprocaine
A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed

Active Comparator: Mepivacaine Drug: Mepivacaine
A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed

Active Comparator: General Anesthesia Drug: General Anesthetics
General anesthetics will be administered intravenously

Primary Outcome Measures :
  1. Readiness for discharge [ Time Frame: Determine within 24 hours after surgery ]
    Defined as duration from arrival in the post-anesthesia care unit (PACU0 to the time patient meets the discharge criteria from the post anesthesia discharge scoring system (PADSS) for home readiness after ambulatory surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients scheduled for a knee arthroscopy that is anticipated to be less than one hour
  • Age 18 to 80 years
  • Ability to follow study protocol
  • English speaking

Exclusion Criteria:

  • Hepatic or renal insufficiency
  • Younger than 18 years old and older than 80
  • Allergy or intolerance to one of the study medications
  • Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
  • Chronic opioid use (taking opioids for longer than 3 months)
  • Patients unable to undergo a spinal anesthetic or Laryngeal Mask Airway (LMA)/GA or patient refusal to spinal anesthesia or LMA/GA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03365752

Layout table for location contacts
Contact: David Kim, MD 212 774 2602
Contact: Nicole Brunetti, BS 6467146794

Layout table for location information
United States, New York
Hospital for Special Surgery Recruiting
New York, New York, United States, 10021
Contact: David Kim, MD    646-714-6794   
Sponsors and Collaborators
Hospital for Special Surgery, New York
Layout table for investigator information
Principal Investigator: David Kim Hospital for Special Surgery, New York

Layout table for additonal information
Responsible Party: Hospital for Special Surgery, New York Identifier: NCT03365752     History of Changes
Other Study ID Numbers: 2017-1547
First Posted: December 7, 2017    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Local
Sensory System Agents
Peripheral Nervous System Agents